Tesamorelin
Also known as: Egrifta, Egrifta WR, Egrifta SV
Status
FDA-approved. Approved since 2010 — but only for HIV-associated lipodystrophy, which makes it the clearest example of 'a real drug, a narrower label than the conversation about it'.
What it is
A growth-hormone-releasing hormone (GHRH) analogue — 44 amino acids, a modified copy of your hypothalamus's own signal to the pituitary. The approved use is reducing excess abdominal fat in people with HIV lipodystrophy.
Source
FDA prescribing information (Egrifta)
Sources
Educational use only, never medical advice. No doses.